AMPs with dual antimicrobial and anticancer activities (i.e., ACPs) are promising therapeutic agents, which can be used to combat HCC as a stand-alone treatment, or as part of a synergistic treatment regimen. The gene discussed is AASDHPPT; the disease is hepatocellular carcinoma.